Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arvinas stock | $72.74

Learn how to easily invest in Arvinas stock.

Arvinas, Inc
+$2.46 (+2.52%)

Arvinas, Inc is a biotechnology business based in the US. Arvinas shares (ARVN) are listed on the NASDAQ and all prices are listed in US Dollars. Arvinas employs 179 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Arvinas

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARVN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arvinas stock price (NASDAQ: ARVN)

Use our graph to track the performance of ARVN stocks over time.

Arvinas shares at a glance

Information last updated 2021-07-28.
Latest market close$72.74
52-week range$19.68 - $108.43
50-day moving average $80.13
200-day moving average $73.67
Wall St. target price$113.85
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.16

Buy Arvinas shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arvinas stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arvinas price performance over time

Historical closes compared with the close of $72.74 from 2021-05-28

1 week (2021-07-23) N/A
1 month (2021-07-02) -8.94%
3 months (2021-05-03) 3.93%
6 months (2021-01-30) N/A
1 year (2020-07-30) N/A
2 years (2019-07-30) N/A
3 years (2018-07-30) N/A
5 years (2016-07-30) N/A

Arvinas financials

Revenue TTM $21.1 million
Gross profit TTM $21.8 million
Return on assets TTM -18.55%
Return on equity TTM -33.51%
Profit margin 0%
Book value $12.61
Market capitalisation $5 billion

TTM: trailing 12 months

Shorting Arvinas shares

There are currently 3.1 million Arvinas shares held short by investors – that's known as Arvinas's "short interest". This figure is 5.7% up from 2.9 million last month.

There are a few different ways that this level of interest in shorting Arvinas shares can be evaluated.

Arvinas's "short interest ratio" (SIR)

Arvinas's "short interest ratio" (SIR) is the quantity of Arvinas shares currently shorted divided by the average quantity of Arvinas shares traded daily (recently around 537182.98245614). Arvinas's SIR currently stands at 5.7. In other words for every 100,000 Arvinas shares traded daily on the market, roughly 5700 shares are currently held short.

However Arvinas's short interest can also be evaluated against the total number of Arvinas shares, or, against the total number of tradable Arvinas shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arvinas's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Arvinas shares in existence, roughly 60 shares are currently held short) or 0.0709% of the tradable shares (for every 100,000 tradable Arvinas shares, roughly 71 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arvinas.

Find out more about how you can short Arvinas stock.

Arvinas share dividends

We're not expecting Arvinas to pay a dividend over the next 12 months.

Arvinas share price volatility

Over the last 12 months, Arvinas's shares have ranged in value from as little as $19.68 up to $108.43. A popular way to gauge a stock's volatility is its "beta".

ARVN.US volatility(beta: 2.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arvinas's is 2.006. This would suggest that Arvinas's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arvinas overview

Arvinas, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc. , Genentech, Inc. , F. Hoffman-La Roche Ltd.

Frequently asked questions

What percentage of Arvinas is owned by insiders or institutions?
Currently 12.321% of Arvinas shares are held by insiders and 89.53% by institutions.
How many people work for Arvinas?
Latest data suggests 179 work at Arvinas.
When does the fiscal year end for Arvinas?
Arvinas's fiscal year ends in December.
Where is Arvinas based?
Arvinas's address is: 5 Science Park, New Haven, CT, United States, 06511
What is Arvinas's ISIN number?
Arvinas's international securities identification number is: US04335A1051
What is Arvinas's CUSIP number?
Arvinas's Committee on Uniform Securities Identification Procedures number is: 04335A105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site